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Abstract: Antibody discovery has become increasingly important in almost all areas of modern
medicine. Different antibody discovery approaches exist, but one that has gained increasing interest
in the field of toxinology and antivenom research is phage display technology. In this review,
the lifecycle of the M13 phage and the basics of phage display technology are presented together with
important factors influencing the success rates of phage display experiments. Moreover, the pros
and cons of different antigen display methods and the use of naïve versus immunized phage display
antibody libraries is discussed, and selected examples from the field of antivenom research are
highlighted. This review thus provides in-depth knowledge on the principles and use of phage
display technology with a special focus on discovery of antibodies that target animal toxins.
Keywords: antibody discovery; recombinant antivenom; phage display; M13 phage; toxinology
Key Contribution: Antibody phage display technology is thoroughly presented and discussed in
relation to antivenom research and toxinology.
1. Introduction
With the recent inclusion of snakebite envenoming on the World Health Organization’s list
of Neglected Tropical Diseases [1], focus on both prevention and treatment of this infliction has
increased. This creates renewed hope for snakebite victims worldwide and could potentially lead to
a mobilization of scientific efforts toward the development of novel snakebite envenoming therapies.
Several different avenues aimed at bringing innovation into the field of snakebite antivenoms have
been pursued, including medicinal chemistry approaches, novel immunization techniques, and the
use of biotechnological strategies [2–5]. One promising approach seems to be the use of human IgG
antibodies [6] and/or camelid antibody fragments [7,8], as these molecules can be used to develop
recombinant antivenoms with high efficacy and safety due to their compatibility with the human
immune system [2]. Moreover, these therapeutic proteins could be manufactured cost-competitively
using modern cell cultivation methods employed for large scale production [6,9]. To discover and
develop antibodies, different techniques can be harnessed. One approach is phage display selection [10],
which is a robust, easy-to-perform, and inexpensive method by which specific antigen binders are
selected from large combinatorial libraries containing billions of antibody fragments.
As antibody phage display is gaining increasing interest in the field of toxinology, the intention
with this review is to provide both basic and more advanced knowledge on the underlying science
behind the technology and the lifecycle of the M13 phage.
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2. The M13 Bacteriophage
Central to phage display technology is the biology of the bacteriophage used to display antibodies.
Different bacteriophage systems can be utilized for phage display, including the T4, lambda, as well as
the filamentous M13 bacteriophage [11]. These different phage systems each have their benefits and
drawbacks. However, primarily the M13 phage has been utilized extensively in recent times, and to the
best of our knowledge, this is the only phage system that has been explored within toxinology [2,12].
Therefore, this review will focus on antibody phage display techniques utilizing this specific phage
system. Before giving an in-depth description of the steps involved in phage display experiments,
an introduction to the wild-type M13 phage is provided.
The M13 phage [13] belongs to a group of filamentous phages collectively referred to as Ff
phages [14]. The Ff phages only infect Escherichia coli strains that express the F pilus as the adsorption
of the phage to the bacterium requires binding of a phage coat protein to the tip of the F pilus [15].
The M13 phage is neither temperate nor lytic. Instead, the phage establishes a chronic infection in its
host, where it continuously releases new phages. The phage contains a genome of single-stranded
DNA (ssDNA) with a length of 6407 bp [16] that consists of nine genes encoding 11 different proteins.
Five of these proteins are coat proteins, and the remaining six proteins are involved in replication
and assembly of the phage. The M13 phage has a length of 900 nm and a width of 6.5 nm [17].
The most abundant of the coat proteins is the capsid protein G8P, which forms an envelope around
the chromosome consisting of approximately 2700 protein units (Figure 1). The remaining four coat
proteins, G3P, G6P, G7P, and G9P, are each present in approximately five copies. Information on the
genes and proteins of the M13 phage is listed in Table 1.
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Figure 1. Schematic representation of the t ri age, hich is a filamentous phage carrying
a single-stranded DNA (ssDNA) chro oso e. e genome contains nine genes, which encode 11
proteins. Five of these proteins are coat proteins (G3P, G6P, G7P, G8P and G9P), while the remaining six
proteins are used for replication of the genome, assembly of the phage, and phage extrusion.
Table 1. Gene name, protein name, protein size, and the function of the genes carried by the M13 phage [16].
Gen Name Protein Name (Abbreviation) Size (kDa) Function
I
Gene 1 protein (G1P) 39.6 Assembly
Gene 11 protein (G11P) 12.4 Assembly
II
Replication-associated protein (G2P) 46.2 Replication
Gene 10 protein (G10P) 12.7 Replication
III Attachment protein (G3P) 44.7 Coat protein Adsorption and extrusion
IV Virion export protein (G4P) 45.9 Assembly and extrusion
V DNA-binding protein (G5P) 9.7 Replication
VI Head virion protein (G6P) 12.4 Coat protein Infection and budding
VII Tail virion protein (G7P) 3.6 Coat protein Assembly and budding
VIII Capsid protein (G8P) 7.6 Coat protein
IX Tail virion protein (G9P) 3.7 Coat protein Assembly and budding
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The first stage of the M13 infection is the adsorption process, which takes place through binding
of the N2 domain of the G3P coat protein to the tip of a F pilus on the surface of E. coli hosts
(Figure 2) [18–20]. Under normal conditions, “male” E. coli cells (F+, containing F-pili) appear to trawl
the environment in an effort to catch “female” (F−) E. coli partners by a series of F-pilus assembly
and disassembly events [21]. Upon phage binding to the tip of one of these F pili, disassembly will
automatically bring the phage closer to the surface of the bacterium [18]. Contact between the G3P-N2
domain and the F pilus mediates the allocation of the G3P-N1 domain and allows it to bind TolA,
which then functions as a co-receptor on the surface of the bacterium. Three Tol proteins are present in
E. coli; TolA, TolR, and TolQ, and all are essential for infection by mediating depolymerization of the
phage coat and translocation of the ssDNA into the bacterium [20,22–25].
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Figure 2. Infection of Escherichia coli by the M13 phage. The phage G3P binds to the tip of the F pilus on
E. coli. Normal disassembly of the F pilus transports the phage to the surface of the bacterium, where it
interacts with the TolA receptor, mediating uptake of the phage genome.
Once the chromosome of the phage has been injected into the bacterium, the host DNA synthesis
machinery will synthesize a DNA (−) strand complementary to the ssDNA (+) strand of the M13
phage. The two strands form a supercoiled double-stranded DNA (dsDNA) phage chromosome,
term d the replicative form (RF) (Fig re 3A) [26]. Replication of the M13 chromosome lways uses
the RF and is carried out by continuous rolling circle repl ation. Ini i tion of replic tion starts
when G2P has accumulated to a concentration that allows it to nick the (+) strand in the RF and
bind covalentl to th 5′ e d (Figure 3B). The 3′ end that is generated from the nick will then be
elongated by DNA polymer se using the (−) strand as a template. Throughout the elongation process,
the original G2P-bound (+) strand is physically displaced by the Rep helicase [27,28] (Figure 3C).
When one round of replication is completed, the old (+) strand is cut off at the origin by a new
G2P, which remains bound to the new 5′ end. After dissociation from the RF, the old (+) strand is
re-circularized, ready to be converted into an RF or to be packaged into new M13 phages (Figure 3D).
In the early stages of infection, all newly formed ssDNA (+) chromosomes will be converted into
RFs, but in later infection stages, where the concentration of G5P is sufficient for fast sequestering
of (+) strands, formation of RFs will be prevented. When the G5P binds the ssDNA, it dimerizes in
a back-to-back conformation leading to the conversion from the circular appearance of the ssDNA to
a more rod-shaped appearance (Figure 3E) [29]. The entire phage chromosome is covered by the G5P
except for an exposed hairpin loop termed the packing signal [30]. The packing signal is required for
packing of the phage genome. G10P plays an essential but unknown role for the stable accumulation
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of ssDNA (+) strands. The ssDNA bound by the G5P protein is the substrate for phage assembly
(Figure 3F).
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concentration of G5P has accumulated to sufficient levels to sequester the ssDNA (E) When sufficient
G5P is accumulated, G5Ps will bind the ssDNA in a back-to-back dimeric conformation, causing the
more rod-shaped appearance of the ssDNA (F) A pore is formed in the membrane, and the phage
genome is translocated through this pore, while the phage coat is assembled.
Assembly and budding of the M13 phage is a five-step process that includes: preinitiation,
initiation, elongation, pretermination, and termination. During preinitiation, an assembly complex
is formed, consisting of G1P, G11P, and G4P, all interacting through their periplasmic domains.
A cylindrical structure, consisting of 12-14 G4P monomers, mediates close contact between the
cytoplasmic membrane and the outer membrane. In addition to a large structure generated by
G4P, a multimeric complex containing five to six copies of both G1P and G10P is generated, potentially
forming a second channel [22].
Initiation awaits formation of the assembly complex during preinitiation as well as accumulation
of G5P-bound M13 chromosomes, and subsequently positions G7P and G9P at the tip of the complex.
Here, G7P and G9P interact with the packing signal in the phage chromosome, which facilitates contact
with the G1P, resulting in binding of thioredoxin from the cell [31].
During the elongation step, the G5P bound to the phage genome is replaced with G8P for
translocation of the DNA through the membrane-spanning channel (Figure 3F). The translocation
continues until the phage genome has become completely coated with G8P, at which point G3P and
G6P will collaborate in the release of the phage from the bacterium. If either G3P or G6P is missing,
additional phage ge omes can be loaded through the pore resulting in formation of a much longer
phage particle [32,33].
Dur ng pretermination, membrane-embedded G3Ps complexed with G6Ps are incorporated at the
terminal end of the phage particle. Termination involve the releas of the phage, brought abou by
a conformational c ange in the G3P-G6P complex [32,34].
Toxins 2018, 10, 236 5 of 15
3. Using the M13 Phage as a Tool in Antibody Discovery
Phage display technology was demonstrated in 1985 by Smith, who successfully incorporated
foreign DNA into the M13 phage chromosome such that foreign peptides were fused to the G3P
coat protein of the M13 phage [35]. Five years later, antibody phage display selection was first
described by McCafferty et al., who were able to fuse genes encoding an entire antibody binding
domain (in the form of single-chain variable fragments, scFvs) to gene III (Figure 4) [36]. This approach
facilitated a sufficient level of antibody display on the outer surface of the phage virion to permit
selection of antigen-recognizing phages [36]. The method thus exploits the possibility of directly
linking a protein (phenotype) to its cognate gene (genotype) through a phage. Since 1990, different
antibody formats have been employed in the construction of antibody-displaying phage libraries,
including heavy-domain human antibody fragments (VHs), heavy-domain camelid and shark antibody
fragments (VHHs), scFvs, diabodies (bivalent scFvs), and entire fragments antigen binding (Fab)
antibodies [37–40]. Generally, these antibody fragments are fused to the G3P of the M13 phage
(Figure 4), and by cloning large numbers of genes encoding an antibody fragment, large phage
display antibody libraries can be generated from which many diverse antibodies can be selected.
As an example, Schofield et al. successfully selected more than 7200 recombinant antibodies to 292
antigens from a human scFv library containing 1.1 × 1010 clones [41].
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4. Phage and Phagemid Libraries
In the earliest examples, antibody genes were cloned directly into the filamentous phage genome,
which carries all the genes needed for infection, replication, assembly, and budding while also carrying
the gene encoding the antibody-G3P fusion. Since each phage particle normally incorporates three to
five copies of G3P, the use of phage vectors potentially results in a multivalent display of antibody-G3P
fusion proteins (although proteolytic degradation can result in removal of a proportion of the fused
antibody). As an alternati e, phagemid vectors based o smaller “minimal plasmids” may be used.
Phagemid vect rs contain three key elem nts (i) a antibiotic marker for selection and propagation of
the plasmid (ii) the gene enc ding the ant body-G3P fusion protein, and (ii ) the regions of the M13
chromosome (phage rigin of replica io ) requ red for rolling circle amplification and the production
of the (+) DNA strand that is capable of being p ckaged into a phage. In rder to produce functional
phage particles displaying antibody-G3P fusion, E. coli harboring a phagemid vector is infected with
a “helper phage”. The helper phage contains the complete M13 genome encoding all the phage
proteins needed for capsid production, phage assembly, chromosome replication, and budding (the
concept of helper phage is described in Section 5 in detail). Upon infection, wild-type G3P from the
helper phage competes with the phagemid encoding the G3P-scFv fusion protein for incorporation
into the phage. Ninety percent of the resulting phage population do not display any fusion protein and
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the vast majority of the phage particles that bear the fusion protein will only contain a single copy [42].
Phagemid vectors are more typically used in library construction than phage vectors because higher
transformation efficiencies can be achieved facilitating the construction of larger libraries. In a direct
comparison of libraries created using phage versus phagemid vectors, it was shown that a greater
diversity of antibody binders was generated from libraries built using the phage vectors rather than
phagemid vectors. The phage system allows for the emergence of a wider range of antibody affinities
compared to the phagemid system [43]. Although the phage system is often referred to as a polyvalent
display and the phagemid system as monovalent, in practice degradation occurs in both cases, and the
beneficial effects of a phage vector-based system may also be attributed to the presence of a higher
proportion of non-bald phage particles. Methods have been developed to restore antibody display
levels in phagemid libraries to the same levels achieved in phage vector-based systems. This is based
on the use of helper phages, which do not encode G3P (the so called hyperphage system [44]), so that
only the G3P-scFv encoded by the phagemid is available for presentation. Since G3P is needed for
packaging and infection of the helper phage and the hyperphage genome lacks the gene encoding
G3P, it is necessary to provide this in trans by using bacteria which express G3P from within the
bacterial genome.
5. Phagemid Libraries Are Amplified Using Helper Phages
As mentioned earlier, an M13 helper phage is used for packaging of phagemid particles in E. coli.
The helper phage carries all genes necessary for infection, replication, assembly, and budding and
therefore provides the phagemid, which primarily carries the gene encoding the G3P-scFv fusion
protein, with the proteins needed for amplification. One such helper phage is the M13KO7 phage [45].
This helper phage carries a heterologous, low copy origin of replication from the plasmid p15A
inserted within the native M13 origin of replication. When the M13KO7 phage is present alone in
a host bacterium (i.e., during preparation of helper phage), the replication is sufficient for producing
high titers of M13KO7 phage. However, if a high copy number phagemid with an intact M13 origin
is present, this will out-compete the helper plasmid during packaging, meaning that the majority
of resulting phage particles will carry phagemid DNA [45]. The resultant phagemid particles will
incorporate G3P encoded by the helper phage genome as well as G3P-scFv encoded within the
packaged phagemid. In practice, there is preferential incorporation of the wild-type G3P from the
helper plasmid, meaning that the majority of the phagemids will be ‘bald’ (not displaying an antibody
fragment). The preferential presentation of G3P rather than the G3P-scFv fusion is probably due to
a combination of differences in expression/translation levels and the fact that a proportion of the
G3P-scFv fusion is degraded (Figure 5). An overview of which genetic elements are carried by the
phagemid and the helper phage is provided in Table 2.
Table 2. Genetic elements carried by phagemids and helper phages.
Genetic Element Phagemid Helper Phage
Gene I X
Gene II X
Gene III X
Gene IV X
Gene V X
Gene VI X
Gene VII X
Gene VIII X
Gene IX X
Gene III-scFv X
Antibiotic resistance gene X X
Origin of replication X
Origin of replication (inefficient) X
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Figure 5. Gene III product from helper phage and gene III-scFv product fro phagemid. The helper
phage carries the gene e coding a trypsin-sensitive ‘bald’ G3P. The phagemid carries the gene encoding
the G3P-scFv fusion protein. As M13 phages will be assembled with three to five copies of G3P,
the number of assembled phages containi g more than one G3P-scFv fusion protein will be too l w
to influence th outcome of selections, becaus more ‘bald’ G3P than G3P-scFv fusion proteins will
be express d. Thereby, th majority of the scFv-displaying phagemids will only be carrying one scFv
(mono alent display).
Bald phages do not participate i siti e antibody: antigen selectio and only contribute
to background noise ithin the system. It is possible to reduce the background noise from this
population by rendering them non-infectious. This is achieved by engineering gene III within the
helper phage to render the encoded G3P sensitive to trypsin [46]. Trypsin treatment before infection
will result in inactivation of bald phages, which rely on labile G3P encoded by the helper phage
(Figure 6). In contrast, phages carrying a G3P-scFv fusion, encoded by the phagemid, will be resistant
to G3P disruption and will retain infectivity after trypsin treatment (As previously shown in Figure 4,
the G3P-scFv fusion protein encoded by the phagemid contains a trypsin cleavage site, but this is
situated between the scFv and the G3P, and thereby does not prevent infection (Figure 6)).
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Figure 6. Trypsin treat ent of 3P and G3P-scFv fusion proteins on the M13 phage. G3P encoded
by the helper phage is trypsin-sensitive and can thus be cleaved by trypsin, rendering the phage
non-infective. In contrast, the G3P-scFv fusion protein encoded by the phagemid contains a myc-tag in
the linker between the G3P and the scFv, which will be cleaved during trypsin treatment. This leaves
a G3P on the phage, rendering it infective.
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6. Performing a Phage Display Selection Experiment
Phage display selection is a high throughput method used to discover antibodies specific to
different antigens. The protocol includes rounds of five steps (Figure 7). The first step is addition
of a phage library, where the library is added to a well or vial in which the antigen is presented
(Figure 7A). Antigen presentation can be achieved via direct coating (adsorption) or via a capture
system (such as streptavidin-biotin). The second step involves binding, where the phages displaying
the highest affinity antibodies bind the epitopes of the antigen (Figure 7B), after which the vial is
washed to remove non-binding phages (Figure 7C). After washing, the bound phages are eluted by
enzymatic digestion using trypsin or by other means of elution (e.g., dilute acid or base) (Figure 7D).
When enzymatic digestion is employed, this step renders bald phages non-infective [46] (Figure 6),
thereby improving the selection of antibody-displaying phages that are still infective (see previous
section). In the fifth step, helper phages are added to allow for amplification of the eluted infective
phages in E. coli (Figure 7E). To accumulate phages displaying high affinity antibody fragments, these
five steps are usually repeated 1-3 times with the amplified phages from the preceding round of
panning. Titration of phage output numbers may also be utilized to monitor progress, and polyclonal
phage ELISA used to confirm selection of a population of binders.
Selections can also be performed in solution with a subsequent pull-down step to isolate high
affinity scFv-displaying phages that are bound to the antigen (which typically needs a tag that can be
pulled down, such as a biotin moiety) [47]. This may also serve to avoid antigen immobilization via
hydrophobic regions, which may diminish the accessibility of relevant epitopes as discussed below.
Conceptually, selections performed in solution include the exact same steps with a few practical
changes. Selections in solution may be beneficial for certain antigens, which better retain proper
folding and conformation that resembles the native antigen protein. Possibly, this is particularly useful
for antigens that natively exist in solution (e.g., blood factors, toxins, cytokines, and hormones).
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Figure 7. The five steps in a phage display selection experiment. Addition of phage library (A) refers
to the addition of phages to an antigen-coated vial. The phages displaying the highest affinity scFvs
will bind (B) the antigen, while unspecific binders will be removed during the washing step (C).After
washing, the antigen-specific phages can be eluted (D) using trypsin digestion (or other means of
elution) Then, phages are amplified (E) in E. coli and a new panning round can be initiated to further
accumulate phages displaying high affinity antibody frag ents. Binding can be evaluated using both
ELISA and plate tests.
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7. Antigen Quality and Presentation
In addition to having a phage display library of high quality, the most crucial element for the
success of a phage display selection experiment is antigen presentation. Different methods of antigen
presentation exist with different advantages and disadvantages (Figure 8) [48,49]. The simplest
method of antigen presentation is to coat the antigen directly to the plastic surface of a well or vial
via adsorption. The major disadvantage of direct immobilization is that the antigen might undergo
conformational changes upon binding to the well or vial surface, potentially leading to conformational
distortion or denaturation of the antigen. Selection of antibodies against a distorted or denatured
antigen will result in accumulation of phages displaying antibodies with high affinity to the distorted
antigen but low affinity to the native antigen in its proper conformation. Additionally, antigens might
have preferences regarding how they bind to the surface, which might result in areas of the antigen
not being properly exposed for interaction. Therefore, very few phages displaying antibodies with
high affinity to such an area can be selected, which is problematic if this area is important to target for
antigen neutralization.
Antigen presentation by immobilization through a streptavidin-biotin capture system requires
that the antigen is chemically conjugated to a biotin moiety via a linker. Biotinylation of an antigen
can be a challenging task, especially since the biotin-to-antigen ratio can be crucial but difficult to
control. Over-biotinylation of the antigen may heavily decrease the available surface area on the
antigen, thereby preventing phage binding. Also, over-biotinylation may alter the physico-chemical
properties of the antigen, possibly leading to undesirable effects, such as antigen aggregation. The main
advantage of immobilization through a biotin linker is that the antigen will be lifted from the plastic
surface of the vial bottom by first coating the vial with streptavidin (or neutravidin) and then adding
the biotinylated antigen to be captured. This allows for an improved display of the antigen and thus the
selection of phages displaying relevant antibodies against more antigen epitopes [48]. A disadvantage
of immobilization through a biotin linker is that addition of streptavidin (or neutravidin) introduces
an additional macromolecule that the phage can bind to, which may lead to accumulation of phages
with streptavidin/neutravidin-binding antibodies. To avoid this issue, deselection steps must be
implemented in the phage display protocol when working with antigens that are immobilized using
such capture systems.
Regarding optimal antigen display via capture systems, it can be worthwhile to consider which
coupling chemistry should be employed. The benefit of having a site-specific coupling reagent includes
greater control; however, this may in some cases have a negative interference with a potential binding
site, which may lead to poor selection. As an example, site-specific coupling to the N-terminal is likely
to be suboptimal if the N-terminal region is part of an important epitope-paratope interaction.
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Figure 8. Antigen immobilization strategies. Direct coating can result in denaturation of the antigen or
distortion of its conformation, whereas immobilization through a streptavidin-biotin capture system,
involving biotinylation of the antigen, can give rise to over-biotinylation resulting in low availability of
binding sites.
8. Naïve versus Immunized Phage isplay ti i r ri
Phage display antibody libraries can be derived from either non-immunized (naïve) or immunized
donors depending on whether the donors, from which the antibody genes were isolated and used to
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create the library, have been immunized with an antigen or not. The benefit of naïve libraries (often
from the IgM repertoire from non-immunized donors) is that it can be used for discovery of a wide
range of antigens, although the discovered antibody fragments may generally have lower affinities
than antibodies discovered from an immunized source [7,50]. In a phage display antibody library
from an immunized source (from the IgG repertoire), the antibody fragments have increased affinity
towards the type of antigen used for immunization as the antibodies have gone through an in vivo
affinity maturation process. This can be an advantage in antibody discovery as it will more easily
generate high affinity hits. Antibodies from the IgG pool of immunized sources will generally have
less diversity than naïve IgM-based libraries, and they are therefore not as broadly applicable in terms
of their antigen scope.
Different techniques can be employed for in vitro affinity maturation of antibody fragments
from naïve phage libraries. The basic principle of in vitro affinity maturation is to first diversify the
sequences of the antibody fragments and then carry out new rounds of phage display selections to
select antibody fragments with increased affinity to the target antigen. Several different methods to
achieve diversification exist. One such method is chain shuffling [51], where the antibody fragments
obtained after selection either have their heavy or their light chain replaced with the full repertoire of
this chain from a naïve library (often the same library from which the initial antibody fragment was
selected) (Figure 9A). Thereby, a new phage display antibody library is created with a constant heavy
or light chain and the full range of the opposite chain as partners (i.e., one heavy chain combined
with all available light chains, or one light chain combined with all available heavy chains). Phage
display selections are then conducted again to identify the best match between heavy and light chains,
which often results in antibody fragments with increased affinity to their targets. Other methods of
diversification used for in vitro affinity maturation employ mutagenesis of the variable regions of
the antibodies. These mutations can either be introduced through random mutagenesis of the whole
variable region of the antibodies [52] (Figure 9B) or through different types of site-directed mutagenesis
techniques that specifically target the different complementarity-determining regions (CDRs) in the
variable regions of the antibodies (Figure 9C) [53].
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shuffling (A) is where one heavy or light chain is paired with chains of the opposite type from a naïve
library. The principle of both light and heavy chain shuffling is presented in the figure. Random
mutagenesis (B) is used to introduce mutations (red lines) in the entire variable regions of the antibody
fragment. Site-directed mutagenesis (C) is used to specifically introduce mutations in one or more of
the complementarity-determining regions (CDR) regions of the antibody fragment.
9. Selected Examples of the Use of Antibody Phage Display Selection within Toxinology
Phage display selection has been employed in the field of toxinology to obtain antibody fragments
with specificities to different toxins [3] and was first employed within snakebite antivenom research
in 1995 by Meng et al., who used a murine scFv library to discover antibody fragments against
crotoxin from Crotalus durissus terrificus [54]. The employed scFv library was affinity matured as it
was generated from mice that had been immunized with crotoxin. The dissociation constant between
one obtained scFv and crotoxin was determined to be 7.0 × 10−10 M, reflecting a very strong binding
interaction between the antibody fragment and the target toxin. The antibody fragment was tested for
its ability to inhibit phospholipase A2 activity in vitro without any effects even at 5:1 antibody-to-toxin
molar ratios. However, the scFv successfully delayed death and in some cases even prevented death in
mice injected with lethal doses of Mojave toxin (a crotoxin homolog) pre-incubated with the scFv [54].
Since 1995, phage display technology has been employed using different target toxins from
different animal species (including snake, scorpion, spider, and bee toxins), using libraries containing
murine, human, and camelid antibodies [2,12]. As an example, Kulkeaw et al. were the first to use
a human antibody phage display library [55]. This library consisted of human svFvs and was used
to discover antibody fragments against α-cobratoxin (a long chain α-neurotoxin) from Naja kaouthia.
The scFvs selected from this library were tested for their ability to neutralize one LD100 of α-cobratoxin
upon pre-incubation of each scFv and the toxin in vivo. This experiment demonstrated that the selected
human scFvs mainly provided prolonged survival of the mice and failed to protect them from lethality.
However, the best scFv was able to protect 33% (2/6) of the mice administered with scFv and toxin
from death. In comparison, Richard et al. employed a llama VHH phage display library to discover
antibody fragments against α-cobratoxin from N. kaouthia [7]. Here, the library was affinity matured
as it was based on VHH genes from a llama immunized with N. kaouthia crude venom. The obtained
antibody fragments had dissociation constants as low as 4 × 10−10 M and proved effective both in
protecting and rescuing mice in a lethality study at antibody-to-toxin molar ratios as low as 0.75:1.
Several examples of phage display selection being employed for discovery of antibody fragments
with specificity to scorpion toxins can be found in the literature. One such example was reported by
Rodríguez-Rodríguez et al., where a human scFv library was used to discover scFvs against Mexican
scorpion venom toxins [56]. Here, scFvs with the ability to bind Cn2 toxin (a β-neurotoxin) from
Centruroides noxius were discovered. However, the scFvs were not able to neutralize the Cn2 toxin
in vivo. To improve the affinity of the antibody fragments, in vitro affinity maturation methods
involving directed evolution, site-directed mutagenesis, and random mutagenesis were employed.
As a result, the researchers successfully improved an scFv to become effective in protecting mice
from both the Cn2 toxin from C. noxius, the Cll1 toxin from Centruroides limpidus, the Css2 toxin from
Centruroides suffusus, and whole venom from C. suffuses [56]. Another example is provided by Pucca et
al., where the human scFv library, Griffin.1, was employed to discover scFvs against Tityus serrulatus
toxins [57]. One obtained scFv was investigated for its neutralizing abilities both through in vitro
biochemical assays and in a murine model, where it showed partially neutralizing effects. In a later
study of the same scFv, it was additionally shown that the scFv could neutralize the effects of similar
β-neurotoxins from other scorpion genera [58].
Finally, phage display selection has also been employed to discover antibody fragments against
bee venom toxins [59]. In a study by Pessenda et al., the human scFv library, Griffin.1, was used to
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find scFvs against melittin and phospholipase A2 from the Africanized bee Apis mellifera. These scFvs
were shown to inhibit the hemolytic activity of the venom in vitro and displayed the ability to reduce
the edematogenic activity when the scFvs were pre-incubated with the venom and injected into the
paws of mice. Additionally, prolongation of survival was observed when mice were subjected to
lethal doses of venom pre-incubated with the scFvs. However, full protection against lethality was not
observed [59].
In relation to toxin-targeting, it is important to note that although antibodies with specific
toxin-binding specificities can often easily be discovered using phage display selection, such binding
does not necessarily translate into toxin-neutralizing ability in vivo [60–62]. Different modes of toxin
neutralization likely exist [63], and any phage display selection experiment must be followed by
vigorous testing of functional activity of the isolated toxin-binding antibodies, as antibodies binding to
non-neutralizing epitopes may have limited therapeutic value.
10. Closing Remarks
With the renewed international focus on snakebite envenoming, more focus on innovation and
development within the field of antivenom will likely arise. Phage display technology represents
a robust, inexpensive, and easy to perform discovery approach that is particularly suitable for
large-scale antibody discovery projects within antivenom research. In this area, multiple antibodies
against a vast range of different toxin targets need to be developed, and phage display selection
offers the opportunity to do so in a parallelized manner. Although no other animal envenomings
than snakebite are currently included in the World Health Organization’s list of Neglected Tropical
Diseases, these analogous fields may likely benefit from the inclusion of snakebite envenoming on
this list. The use of phage display technology within toxinology and antivenom research is still
at its infancy. However, several promising examples have already been reported in the literature,
supporting the notion that phage display selection is indeed a feasible antibody discovery approach.
Additionally, the many developments and advances within antibody technologies and manufacturing,
championed by other fields, such as oncology and autoimmune and infectious diseases, represent
a golden opportunity that antivenom research may piggy-back on. It therefore seems relevant that
antivenom researchers become acquainted with phage display technology as well as other antibody
discovery approaches.
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